Excision

formerly Excision BioTherapeutics

Gene editing therapeutics company

Excision is a biotech company in San Francisco, United States, founded in 2015. It has raised $60.0M across 4 rounds, most recently a Grant in September 2022.

Employees
11–50
Founded
2015
Business Model
B2B
Total Funding
$60.0M
Last Round
GrantSep 2022
Rounds
4

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 4 funding rounds and 8 investors for this company. to use credits for reveals, or explore the API.

About

Excision BioTherapeutics is a biopharmaceutical company developing in vivo CRISPR-Cas9 and CRISPR-CasX gene-editing therapies designed to cure viral infectious diseases rather than merely suppress them. Its lead candidate, EBT-101, targets latent HIV-1 reservoirs and builds on gene-editing research originated in the lab of Temple University professor Kamel Khalili. The company received FDA fast-track designation for EBT-101 in 2023 and advanced the therapy into early-stage human clinical trials, though a 2024 readout showed it did not maintain viral suppression alone at the initial dose.

Funding History

Data from Indexed.vcUpdated
GrantSep 2022

3 more funding events

  • Series A20217 investors
  • Series A20215 investors
  • Seed20171 investor

Funding: Seed through Grant. Amounts, valuations, and investors where available.

Investors

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

  • Frontend ×3
  • Other ×2
  • DevOps ×1

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Companies in related industries

Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech
Corporate RoundTotal funding$1.0BApr 2020
GRAILIPO

Biotechnology company developing multi-cancer early detection blood tests using high-intensity ge...

Menlo Park, United States1001–5000Biotech
Corporate RoundTotal funding$2.1BJun 2026
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech
Extension RoundTotal funding$1.2BNov 2021
Ultima Genomics

Ultima Genomics develops high-throughput DNA sequencing platforms that use open-wafer technology ...

Fremont, United States201–500Biotech
Series ETotal funding$1.1BJun 2022

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Excision on Indexed.vc
<a href="https://indexed.vc/companies/excision"><img src="https://indexed.vc/api/badge/company/excision" alt="Excision on Indexed.vc" width="260" height="76" /></a>